BioSpace News Archive

Lirum Therapeutics, Inc. announced that it has closed a private placement, which resulted in gross proceeds to Lirum of over $7 million, before deducting offering expenses.

4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced that the Company will present at the SVB Securities Global Biopharma Conference.

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), today announced its consolidated results for the third quarter (Q3) and nine month (9M) ended 31th December 2022.

DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced management will participate at the following investor conferences.

Hyperfine, Inc. announced that Brett Hale will join Hyperfine, Inc. on February 13, 2023 and will serve as Chief Administrative Officer & Chief Financial Officer.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Harlan Weisman, M.D. as permanent Chief Executive Officer.

Azenta, Inc. reported financial results for the first quarter ended December 31, 2022.

BELLUS Health Inc. announced that two abstracts describing the patient medical journey and the negative impact of RCC on quality of life will be presented at the upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting, being held in San Antonio, Texas from February 24-27, 2023.

Travere Therapeutics, Inc. announced that Company management will participate in the following upcoming conferences.

STERIS plc announced financial results for its fiscal 2023 third quarter ended December 31, 2022.